伟思医疗 (688580)
Nanjing Vishee Medical Technology Co., Ltd.
K-Line Chart
No K-line data available
Company NameNanjing Weisi Medical Technology Co., Ltd.
Listing Date2020-07-21
Issue Price67.58RMB
Registered Capital9577.128810k RMB
Legal RepresentativeWang Zhiyu
Registered AddressBuilding 9, No. 19 Ningshuang Road, Yuhuatai District, Nanjing City, Jiangsu Province
IndustryMedical Devices
Main BusinessThe company is a technology innovation-driven enterprise in China's rehabilitation medical device industry. It is committed to providing safe and effective rehabilitation products and integrated solutions to medical and professional institutions in specialized fields such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and psychiatric rehabilitation. Currently, the company's main products include rehabilitation medical devices and products such as electrical stimulation devices, magnetic stimulation devices, electrophysiological devices, consumables, and accessories.
Company ProfileNanjing Weisi Medical Technology Co., Ltd. was founded in 2001 and is a technology innovation-driven enterprise in China's rehabilitation medical device industry. It is dedicated to providing safe and effective rehabilitation products and integrated solutions to professional institutions like hospitals in specialized fields such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and psychiatric rehabilitation. Currently, the company's products mainly include bio-stimulation feedback instruments, magnetic stimulation instruments, etc., covering technical directions such as electrical stimulation, magnetic stimulation, and electrophysiology. Additionally, the company is actively engaged in the research and development of new products like next-generation magnetic stimulation instruments and rehabilitation robots.
The company is positioned in the Chinese rehabilitation market, focusing on niche markets such as electrical stimulation, magnetic stimulation, and electrophysiology. Leveraging years of market understanding and investment, the company adheres to R&D innovation as its development driver and maintains a strategic positioning of leading industry and technological frontiers. It has built solid and diverse technology platforms and competitive product solutions, established a nationwide sales channel network, shaped a strong brand image and academic promotion system, and perfected a customer service system centered on customer satisfaction. This has enabled the company to form comprehensive competitive advantages in technology, products, channels, brand, and service, maintaining a high market share.
Stock Details
1. Key Indicators
- Total Shares(W): 9577.13
- Circulating A-Shares(W): 9577.13
- Earnings Per Share(RMB): 1.0700
- Net Assets Per Share(RMB): 17.3099
- Operating Revenue(W RMB): 32553.03
- Total Profit(W RMB): 11287.42
- **Net Profit Attributable to Parent(W RMB) **: 10214.83
- Net Profit Growth Rate(%): 30.68
- Weighted Return on Equity(%): 6.1700
- Operating Cash Flow Per Share(RMB): 1.0900
- Undistributed Profit Per Share(RMB): 4.7008
- Capital Reserve Per Share(RMB): 11.1345
2. Main Business
The main business covers:
- Research, development, production, and sales of rehabilitation medical devices
3. Company Basic Information
- Company Name: Nanjing Vishee Medical Technology Co., Ltd.
- Listing Date: 2020-07-21
- Industry: Special Purpose Equipment Manufacturing
- Address: Building 9, No. 19 Ningshuang Road, Yuhuatai District, Nanjing City, Jiangsu Province
- Website: https://www.vishee.com/
- Company Profile: On October 8, 2015, approved by the shareholder meeting of Vishee Limited, it was agreed that Vishee Limited would be converted into a joint stock limited company as a whole by converting its audited net assets into shares. The specific plan was: based on the audited net assets of Vishee Limited of RMB 62.8439 million as of July 31, 2015, converted at a ratio of 1:0.79562 into 50,000,000 shares, with a par value of RMB 1.00 per share. The remaining portion was transferred to capital reserve. All shareholders of Vishee Limited subscribed to all the shares using the audited net assets corresponding to their equity in Vishee Limited as capital contribution, maintaining the same equity proportions. Vishee Limited was wholly transformed and established as Nanjing Vishee Medical Technology Co., Ltd. According to the "Audit Report" issued by Tianheng Certified Public Accountants (Tianheng Audit No. [2015]02073), as of the audit base date July 31, 2015, the book value of Vishee Limited's net assets was RMB 62.8439 million. According to the "Assessment Report" issued by Beijing Tianjian Xingye Asset Appraisal Co., Ltd. (Tianxing Su Ping Bao Zi [2015] No. 0051), as of July 31, 2015, the assessed value of Vishee Limited's net assets was RMB 108.5962 million. On October 8, 2015, all shareholders of Vishee Limited signed the "Sponsor Agreement" as promoters. On October 16, 2015, Tianheng Certified Public Accountants issued the "Capital Verification Report" (Tianheng Verification No. [2015]02111), confirming that as of October 16, 2015, Vishee Medical had received a total registered capital of RMB 50.00 million paid by all shareholders. On November 5, 2015, Vishee Medical completed the overall change registration procedures at the Nanjing Administration for Industry and Commerce and obtained the "Business License" with the Unified Social Credit Code: 913201007217994654.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Nanjing Zhida Venture Investment Center (Limited Partnership) | General Legal Person | 780.35 | 8.15 |
| 2 | Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. | General Legal Person | 112.82 | 1.18 |
| 3 | BXRF Health Life Theme Flexible Allocation Mixed Securities Investment Fund | Fund | 7.50 | 0.08 |
5. Concept Sectors
- Childcare Concept
- Elderly Care Concept
- Intelligent Machines
- Medical Aesthetics Concept
- Brain-Computer Interface
- Exoskeleton
- Margin Trading & Securities Lending
- High-Performance Stocks
- Shareholder Reduction
- Intensive Research
- Specialized, Refined, Unique, and New Enterprises
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information
